# Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

> **NCT00052494** · PHASE1 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 9 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** imatinib mesylate
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00052494
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2009-02
- **Final completion:** —
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2015-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00052494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00052494, "Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00052494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*